Fasting Glucose in Acute Myocardial Infarction
| Autor: | Abeer Suleiman, Walter Markiewicz, Doron Aronson, Mahmoud Suleiman, Haim Hammerman, Rafael Beyar, Michael Kapeliovich, Yoram Agmon |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Advanced and Specialized Nursing
medicine.medical_specialty Framingham Risk Score Ejection fraction Proportional hazards model business.industry Endocrinology Diabetes and Metabolism Hazard ratio Metabolic disorder Infarction medicine.disease Endocrinology Internal medicine Diabetes mellitus Internal Medicine medicine Cardiology Myocardial infarction business |
| Zdroj: | Diabetes Care. 30:960-966 |
| ISSN: | 1935-5548 0149-5992 |
| DOI: | 10.2337/dc06-1735 |
| Popis: | OBJECTIVE—Elevation of blood glucose is a common metabolic disorder among patients with acute myocardial infarction (AMI) and is associated with adverse prognosis. However, few data are available concerning the long-term prognostic value of elevated fasting glucose during the acute phase of infarction. RESEARCH DESIGN AND METHODS—We prospectively studied the relationship between fasting glucose and long-term mortality in patients with AMI. Fasting glucose was determined after an ≥8 h fast within 24 h of admission. The median duration of follow-up was 24 months (range 6–48). All multivariable Cox models were adjusted for the Global Registry of Acute Coronary Events (GRACE) risk score. RESULTS—In nondiabetic patients (n = 1,101), compared with patients with normal fasting glucose ( CONCLUSIONS—Fasting glucose is a simple robust tool for predicting long-term mortality in nondiabetic patients with AMI. Fasting glucose provides incremental prognostic information when added to the GRACE risk score and left ventricular ejection fraction. Fasting glucose is not a useful prognostic marker in patients with diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|